LYN OVEREXPRESSION

CI-VAR-00003034Explore in graph →CIViC 2917

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive2
LYN OVEREXPRESSION	Bafetinib + DasatinibSubstitutes	Predictive	D	Does Not Support Resistance	3	accepted	EID7874 The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib showed the most potency against MYL-R compared to the non-resistant MYL cell line (IC50: 6… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
LYN OVEREXPRESSION	Nilotinib	Predictive	D	Supports Resistance	1	accepted	EID7875 The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Nilotinib showed 3.1 times less potency than bafetinib (INNO-406) against MYL-R (IC50: 993.6 nM vs. … (full text at CIViC) PMID 18191450 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm1
LYN OVEREXPRESSION	Dasatinib	Predictive	D	Does Not Support Resistance	3	rejected	EID9085 The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib exhibited similar potency against MYL-R (IC50: 6.4 nM) as compared to MYL cell lines (IC50… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic